监测青光眼的神经退行性变：治疗意义。
Monitoring Neurodegeneration in Glaucoma: Therapeutic Implications.
机构信息
Department of Ophthalmology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.
Department of Ophthalmology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; Department of Developmental Biology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.
出版信息
Trends Mol Med. 2018 Jan;24(1):7-17. doi: 10.1016/j.molmed.2017.11.004. Epub 2017 Dec 7.
Glaucoma is one of the leading causes of blindness globally, and is characterized by loss of retinal ganglion cells (RGCs). Because vision loss in glaucoma is not reversible, therapeutic interventions early in disease are highly desirable. However, owing to the current limitations in evaluating glaucomatous neurodegeneration, it is challenging to monitor the disease severity and progression objectively, and to design rational therapeutic strategies accordingly. Therefore, there is a clear need to identify quantifiable molecular biomarkers of glaucomatous neurodegeneration. As such, in our opinion, molecular biomarker(s) that specifically reflect stress or death of RGCs, and which correlate with disease severity, progression, and response to therapy, are highly desirable.
青光眼是全球导致失明的主要原因之一，其特征是视网膜神经节细胞 (RGCs) 的丧失。由于青光眼导致的视力丧失不可逆转，因此在疾病早期进行治疗干预是非常理想的。然而，由于目前在评估青光眼神经退行性变方面存在局限性，因此难以客观监测疾病的严重程度和进展，并相应地设计合理的治疗策略。因此，非常有必要确定可量化的青光眼神经退行性变的分子生物标志物。因此，我们认为，特异性反映 RGCs 应激或死亡、与疾病严重程度、进展和对治疗的反应相关的分子标志物是非常理想的。
Zotero 插件